Corbus And Janux Lead Q1’s Small-Cap Winners

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.

Nasdaq

A revival in NASDAQ-listed small-cap biopharma stocks (namely, those worth less than $1bn) that started last November looks to be holding reasonably steady. The index is up by nearly 30%, at just over 3,100 points compared with six months ago, although its gains have been eroded by around 7% since late February amid concerns around stubborn US inflation rates.

A look back over the sector’s performance in the first quarter of 2024 using Evaluate Pharma data (based on a...

More from Business

More from Scrip